Andrew Parkinson
Affiliations: | 1987- | University of Kansas Medical Center, Kansas City, KS, United States |
Website:
http://xpd.us.com/expertise.htmlGoogle:
"Andrew Parkinson"Bio:
https://wwwtest.kumc.edu/school-of-medicine/pharmacology-toxicology-and-therapeutics/faculty/volunteer-joint-and/or-graduate-faculty/andrew-parkinson-phd.html
https://books.google.com/books?id=4qEvAQAAIAAJ
Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Stephen Safe | grad student | 1981 | University of Guelph | |
| (Induction of multiple forms of cytochrome P-450 by polychlorinated biphenyls) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kazmi F, Yerino P, Barbara JE, et al. (2015) Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 1294-302 |
| Kazmi F, Barbara JE, Yerino P, et al. (2015) A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 523-33 |
| Eichenbaum G, Skibbe J, Parkinson A, et al. (2012) Use of enzyme inhibitors to evaluate the conversion pathways of ester and amide prodrugs: a case study example with the prodrug ceftobiprole medocaril. Journal of Pharmaceutical Sciences. 101: 1242-52 |
| Parkinson A, Kazmi F, Buckley DB, et al. (2010) System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes. Drug Metabolism and Pharmacokinetics. 25: 16-27 |
| Nassar AE, King I, Paris BL, et al. (2009) An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 1922-30 |
| Parkinson A, Leonard N, Draper A, et al. (2006) On the mechanism of hepatocarcinogenesis of benzodiazepines: evidence that diazepam and oxazepam are CYP2B inducers in rats, and both CYP2B and CYP4A inducers in mice. Drug Metabolism Reviews. 38: 235-59 |
| Juberg DR, Mudra DR, Hazelton GA, et al. (2006) The effect of fenbuconazole on cell proliferation and enzyme induction in the liver of female CD1 mice. Toxicology and Applied Pharmacology. 214: 178-87 |
| Ogilvie BW, Zhang D, Li W, et al. (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions Drug Metabolism and Disposition. 34: 191-197 |
| Parkinson A, Mudra DR, Johnson C, et al. (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicology and Applied Pharmacology. 199: 193-209 |
| Graham RA, Downey A, Mudra D, et al. (2002) In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 1206-13 |